Tag: non alcoholic steatohepatitis biomarkers market segments

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Non Alcoholic Steatohepatitis Biomarkers Market for the Period 2024 to 2033?

The market size for non-alcoholic steatohepatitis biomarkers has seen a significant increase in recent times. It is projected to escalate from $1.11 billion in 2023 to $1.39 billion in 2024, achieving a compound annual growth rate (CAGR) of 25.6%. Factors such as diabetes and metabolic syndrome, increasing awareness and screening initiatives, limitations in liver biopsy, regulatory backing, a shift towards individualized medicine, and clinical testing for NASH, have all contributed to the historical period growth.

There is an anticipated surge in the size of the non-alcoholic steatohepatitis biomarkers market in the approaching years. The market is projected to expand to $3.2 billion in 2028, boasting a compound annual growth rate (CAGR) of 23.1%. This growth during the predicted period can be credited to the introduction of new therapies, the proliferation of precision medicine techniques, efforts from patient advocacy groups, the incorporation of multi-omics data and increased patient involvement. The forecast period also forecasts trends such as telemedicine and remote patient monitoring, the development of novel diagnostic platforms, international research partnerships, progress in biomarker discovery technology, the implementation of artificial intelligence (AI), and the use of imaging biomarkers.

Claim Your Free Sample of the Global Non Alcoholic Steatohepatitis Biomarkers Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

What Factors Are Responsible for the Growth of the non alcoholic steatohepatitis biomarkers Market?

The rise in liver cancer incidents is anticipated to fuel the expansion of the non-alcoholic steatohepatitis biomarkers market. Liver cancer involves the formation of malignant tumors in the liver and may originate directly from the liver (primary liver cancer) or metastasize from different parts of the body (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers serve several purposes in liver cancer, including early detection, monitoring disease progression, evaluating treatment response, offering prognostic details, and decreasing the necessity for invasive procedures. For example, the Journal of Hepatology, a Switzerland-based medical journal focusing on hepatology, noted in October 2022 that recent research suggests the hepatitis B virus (HBV) to be responsible for an estimated 56% of liver cancer cases. Consequently, the escalating incidence of liver cancer is stimulating the growth of the non-alcoholic steatohepatitis biomarkers market.

Which Segments Are Important for Insight into the Non Alcoholic Steatohepatitis Biomarkers Market?

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types

2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

What Are the Significant Trends Reshaping the Non Alcoholic Steatohepatitis Biomarkers Sector?

A leading trend in the non-alcoholic steatohepatitis biomarkers market is the increasing popularity of technological advancements. To consolidate their market positions, major companies are focusing on the development of innovative solutions. For example, in October 2022, GENFIT, a biopharmaceutical company based in France, and LabCorp, a US-based life sciences company, struck an exclusive licensing agreement for five years concerning GENFIT’s NIS4 technology. Created to help identify individuals at risk of non-alcoholic steatohepatitis (NASH), the NIS4 technology is a unique multi-biomarker-based algorithm. It specifically singles out patients with NASH and significant to advanced fibrosis (F > 2), also known as at-risk NASH. Under the terms of this agreement, LabCorp will develop and commercialize a molecular diagnostic test that uses NIS4 technology, allowing healthcare professionals in the US and Canada broad access to the technology.

Order Now for Fast Delivery of Your Non Alcoholic Steatohepatitis Biomarkers Market Report!

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Which Regions Are Essential for the Growth of the Non Alcoholic Steatohepatitis Biomarkers Market?

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Non Alcoholic Steatohepatitis Biomarkers Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the non alcoholic steatohepatitis biomarkers market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Non Alcoholic Steatohepatitis Biomarkers Market Include

1. Non Alcoholic Steatohepatitis Biomarkers Market Executive Summary

2. Non Alcoholic Steatohepatitis Biomarkers Market Segments

3. Non Alcoholic Steatohepatitis Biomarkers Market Size And Template Market Growth Rate

4. Key Non Alcoholic Steatohepatitis Biomarkers Market Trends

5. Major Non Alcoholic Steatohepatitis Biomarkers Market Drivers

……

25. Key Mergers And Acquisitions In The Non Alcoholic Steatohepatitis Biomarkers Market

26. Top Non Alcoholic Steatohepatitis Biomarkers Companies

27. Non Alcoholic Steatohepatitis Biomarkers Market Opportunities And Strategies

28. Non Alcoholic Steatohepatitis Biomarkers Market, Conclusions And Recommendations

29. Appendix

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024, the non-alcoholic steatohepatitis biomarkers market is expected to show promising growth in the forecast period.

The non-alcoholic steatohepatitis (NASH) biomarkers market has witnessed remarkable growth, projected to reach $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 25.6%. Let’s delve into the factors contributing to this growth and the emerging trends shaping the market’s trajectory.

• Liver Cancer Prevalence and NASH Biomarkers Liver cancer, whether primary or secondary, has become increasingly prevalent. Studies suggest that hepatitis B virus (HBV) accounts for about 56% of liver cancer cases. NASH biomarkers play a crucial role in early detection, monitoring disease progression, and assessing treatment response. They provide valuable prognostic information, reducing the reliance on invasive procedures.
• Key Players in the Market Major companies such as Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., and others are actively engaged in the development and commercialization of NASH biomarkers. Their contributions drive innovation and accessibility in the market.

View More On The Non-Alcoholic Steatohepatitis Biomarkers Market Report 2024 – https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Advancements In NIS4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test
Technological advancements are at the forefront of driving growth and innovation in the NASH biomarkers market. Companies like GENFIT and LabCorp are spearheading efforts to introduce novel solutions.

• NIS4 Technology GENFIT’s NIS4 technology, an innovative multi-biomarker-based algorithm, holds promise in identifying patients with NASH and significant to advanced fibrosis. LabCorp’s exclusive licensing deal for NIS4 technology underscores the importance of blood-based molecular diagnostic tests in healthcare.
• Strategic Partnerships Partnerships, such as the one between Novo Nordisk A/S and Echosens SA, aim to advance early diagnosis and raise awareness of NASH. These collaborations facilitate knowledge exchange and promote better patient outcomes.

Segmentation and Regional Outlook
The NASH biomarkers market is segmented based on type, disease, and end use, catering to diverse healthcare needs and preferences. The segmentation includes hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, among others.

• By Region North America emerged as the largest region in the NASH biomarkers market in 2023, while Asia-Pacific is poised to witness the fastest growth during the forecast period. This regional variation underscores the global impact of NASH and the need for concerted efforts in research and development.

Future Prospects and Challenges
Looking ahead, the NASH biomarkers market is projected to reach $3.2 billion by 2028, driven by the emergence of novel therapies and the expansion of precision medicine approaches. However, challenges such as regulatory hurdles and healthcare disparities may impede market growth.

• Key Trends Telemedicine and remote monitoring, innovative diagnostic platforms, and global collaborations are among the key trends shaping the future of the NASH biomarkers market. Integration of artificial intelligence (AI) and inclusion of imaging biomarkers are also poised to revolutionize disease management and diagnosis.

In conclusion, the non-alcoholic steatohepatitis biomarkers market is experiencing unprecedented growth, fueled by technological innovation, strategic partnerships, and increasing disease prevalence. As stakeholders continue to collaborate and innovate, the landscape of NASH diagnosis and treatment is set to evolve, promising better outcomes for patients worldwide.

Request A Sample Of The Global Non-Alcoholic Steatohepatitis Biomarkers Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=9002&type=smp